Get the Stockscreener App
94.53
0.62%
0.4051
Biontech Se Adr stock is traded at $94.53, with a volume of 243.48K.
It is up +0.62% in the last 24 hours and down -0.83% over the past month.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
See More
Previous Close:
$94.12
Open:
$96.2
24h Volume:
243.48K
Relative Volume:
0.22
Market Cap:
$23.93B
Revenue:
$3.32B
Net Income/Loss:
$-1.26B
P/E Ratio:
-18.07
EPS:
-5.2311
Net Cash Flow:
$289.80M
1W Performance:
-4.67%
1M Performance:
-0.83%
6M Performance:
-12.83%
1Y Performance:
+2.09%
1-Day Range:
$94.49
$96.80
1-Week Range:
$90.79
$98.57
52-Week Range:
$79.52
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
94.64 | 23.80B | 3.32B | -1.26B | 289.80M | -5.2311 |
VRTX
Vertex Pharmaceuticals Inc
|
439.51 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
719.87 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.75 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.52 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
317.55 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-16-26 | Upgrade | Goldman | Neutral → Buy |
| Jun-05-25 | Reiterated | H.C. Wainwright | Buy |
| May-29-25 | Initiated | Goldman | Neutral |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Jan-10-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
| Nov-19-24 | Initiated | Berenberg | Buy |
| Nov-19-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-08-24 | Upgrade | Goldman | Neutral → Buy |
| Sep-24-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-16-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-07-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-02-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-14-24 | Initiated | Evercore ISI | In-line |
| Feb-23-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-24 | Initiated | Oppenheimer | Perform |
| Dec-01-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-16-23 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-17-23 | Upgrade | Redburn | Neutral → Buy |
| Dec-15-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-17-22 | Initiated | Cowen | Market Perform |
| Jul-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Dec-16-21 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Aug-11-21 | Upgrade | Bryan Garnier | Neutral → Buy |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-16-21 | Downgrade | Redburn | Neutral → Sell |
| May-18-21 | Initiated | Goldman | Neutral |
| May-11-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Dec-01-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-03-20 | Resumed | Berenberg | Buy |
| Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-30-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-28-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-09-20 | Initiated | H.C. Wainwright | Neutral |
| Jan-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jan-22-20 | Downgrade | UBS | Buy → Neutral |
| Nov-05-19 | Initiated | Wolfe Research | Outperform |
| Nov-04-19 | Initiated | Berenberg | Buy |
| Nov-04-19 | Initiated | BofA/Merrill | Buy |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Nov-04-19 | Initiated | JP Morgan | Overweight |
| Nov-04-19 | Initiated | SVB Leerink | Outperform |
| Nov-04-19 | Initiated | UBS | Buy |
View All
Biontech Se Adr Stock (BNTX) Latest News
BioNTech authorizes $1 billion share buyback program By Investing.com - Investing.com South Africa
BioNTech authorizes $1 billion share buyback program - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
BNTX Stock News: BioNTech Announces Layoffs as Covid-19 Revenue Slides - Barchart.com
BNTX Stock Price, Quote & Chart | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
BioNTech Earnings: Clinical Development on Track, Busy Schedule for the Remainder of the Year - Morningstar
Pfizer Beats on Q1 Earnings, New & Acquired Drugs Drive Sales Growth - sharewise.com
BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape - Benzinga
BioNTech Q1 Earnings Call Highlights - Yahoo Finance
BioNTech Q1 2026 Revenue Miss Overshadows Pipeline Progress as NASDAQ:BNTX Slides - ChartMill
BioNTech earnings ahead: Can oncology offset plunging vaccine sales? - Investing.com
Mitsubishi UFJ Trust & Banking Corp Sells 92,271 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Pictet Asset Management Holding SA Buys 26,119 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech’s Cancer Pivot Faces a Defining Week as Founders Head for the Door () - aktiencheck.de
SanDisk, Western Digital, Clorox And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Sahm
BioNTech (NASDAQ:BNTX) Shares Gap DownWhat's Next? - MarketBeat
Pfizer, BioNTech Defeat Moderna COVID Jab Patent - Law360
BioNTech (BNTX) surges 6.1%: Is this an indication of further gains? - MSN
BioNTech SE Sponsored ADR $BNTX Shares Sold by Flossbach Von Storch SE - MarketBeat
Tangible book value per share of BioNTech SE Sponsored ADR – XETR:22UA - TradingView
BioNTech's $5.5 Million Insider Sale Precedes a Pivotal May for the Biotech () - aktiencheck.de
BioNTech SE (BNTX) Stock Price, Trades & News - GuruFocus
BioNTech SE (MEX:BNTXN) Stock Price, Trades & News - GuruFocus
Sierk Poetting Sells 50,000 Shares of BioNTech (NASDAQ:BNTX) Stock - MarketBeat
BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains? - Yahoo Finance
BioNTech's Oncology Ambitions Hinge on Landmark Data and Shareholder Vote () - aktiencheck.de
Middle East Conflict Weighs on Markets: Food Supply Chains Become a Key Issue – MustGrow, K+S, Evotec, and BioNTech in the Spotlight - news.financial
BioNTech's Pancreatic Cancer Vaccine Shows Unprecedented Long-Term Survival () - aktiencheck.de
BioNTech's Oncology Pipeline Delivers Critical Data as Strategic Pivot Accelerates () - aktiencheck.de
BNTX Earnings History & Surprises | EPS & Revenue Results | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
BioNTech’s Malaria mRNA Vaccine Trial Reaches Completion: What Investors Should Watch - TipRanks
Lbp Am Sa Acquires 15,255 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech Impfung: Between Pandemic Legacy and Oncology Pivot, Future Hinges on Pipeline Wins - AD HOC NEWS
BioNTech SE Sponsored ADR $BNTX Shares Sold by Baillie Gifford & Co. - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: IDEAYA Biosciences (IDYA), BioNTech SE (BNTX) and Stryker (SYK) - The Globe and Mail
BioNTech's Cancer Drug Data Fuels Optimism Amid Financial Headwinds () - aktiencheck.de
Net income of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView — Track All Markets
BioNTech SE Sponsored ADR Revenue Breakdown – BSESOF:22UA - TradingView
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
BioNTech Earnings Call: Cash-Rich Pivot Beyond COVID - TipRanks
BioNTech's $17 Billion War Chest Fuels High-Stakes Oncology Pivot () - aktiencheck.de
Operating income of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView — Track All Markets
BioNTech's Shareholder Vote to Cement Post-Pandemic Strategy () - aktiencheck.de
Why Is Pfizer Stock Dropping Tuesday? - Sahm
European ADRs Slipped As Biotech Lagged And UK Names Rose - Finimize
Leerink cuts BioNTech stock price target on drug trial concerns - Investing.com
BioNTech Shifts Strategy with Dual Operational Pullbacks () - aktiencheck.de
BioNTech's Strategic Pivot: Fueling Oncology Ambition with Capital Reserves () - aktiencheck.de
BioNTech Shares Navigate Dual Challenges Amid Strategic Shift () - aktiencheck.de
BioNTech announces invitation to 2026 annual general meeting for May 15 - Investing.com
BioNTech's mRNA Vaccine Platform: Current Developments and Strategic Importance for North American I - AD HOC NEWS
Biontech Se Adr Stock (BNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.15%
3.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):